AMENDMENTS TO THE CLAIMS

Replace the claims with the following rewritten listing.

1. (Original) An ophthalmic preparation comprising a glycoprotein derived from one of mammalian milk and a milk byproduct.

2. (Original) An ophthalmic preparation in accordance with Claim 1 wherein the glycoprotein component is derived from dairy whey.

3. – 8. (Withdrawn)

9. (Original) An ophthalmic preparation in accordance with Claim 1 wherein the glycoprotein is complexed with at least one component selected from the group consisting of a lipid, phospholipid and lipoprotein.

10. (Original) An ophthalmic preparation in accordance with Claim 9 wherein the lipid component is present in the amount of 0.01% to about 30% of the complex.

11. (Original) An ophthalmic preparation in accordance with Claim 1 wherein the glycoprotein is autoclavable.

12. (Original) An ophthalmic preparation in accordance with Claim 1 further comprising a material selected from the group consisting of a buffering agent; a viscosity modifying agent; a tonicity modifying agent; a humectant compound; and a therapeutic drug.

13. – 18. (Withdrawn)

19. (Original) A therapeutic package for dispensing to, or for use in dispensing to, a patient being treated for dry eye comprising:

one or more unit doses, each such unit dose comprising an amount of glycoprotein therein such that periodic administration of one or more of said unit doses is effective to treat said dry eye condition, and

a finished pharmaceutical container therefore, said container containing said unit dose or multiple doses, said container further including labeling;

said labeling directing the use of said package in the treatment of said dry eye condition in a dosage regimen under which the delivery of said glycoprotein is confined to the period during the day proximate to the time of day at which the patient requires treatment, and further directing the use of said package in conjunction with the concomitant administration to said patient of one or more unit doses providing a therapeutically effective amount of glycoprotein to said patient.

20. (Original) A package according to Claim 19 in which said glycoprotein is substantially free of: lactoferrin; immunoglobulin; beta-lactoblobulin; alpha-lactalbumin; and bovine serum albumin.

21. (Original) A package according to Claim 19 in which the delivery of said glycoprotein is directed to be confined proximate to the time of waking and the delivery of said glycoprotein is confined proximate to the time of onset of sleeping.

22. (Original) A therapeutic package for dispensing to, or for use in dispensing to, a patient being treated for dry eye comprising:

one or more unit doses, each such unit dose comprising an amount of glycoprotein therein such that periodic administration of one or more of said unit doses is effective to treat said dry eye condition, wherein said glycoprotein is substantially free of: lactoferrin; immunoglobulin; beta-lactoblobulin; alpha-lactalbumin; and bovine serum albumin; and

a finished pharmaceutical container therefore, said container containing said unit dose or multiple doses, said container further containing or comprising labeling;

said labeling directing the use of said package in the treatment of said dry eye condition in a dosage regimen under which the delivery of said glycoprotein is one or more times daily, or as directed by a physician.

23. (Original) A package according to Claim 22 wherein said labeling directs the use of said package in the treatment of dry eye induced by an activity selected from the group consisting of: contact lens wear and prolonged viewing of a computer screen.

24. (Original) A package according to Claim 22 that is produced by form, fill and seal manufacturing wherein each container contains from about 0.50 ml to about 1.50 ml of glycoprotein solution.

25. (Original) A package according to Claim 22 comprising a bottle, dropper tip and cap wherein each bottle contains from about 2.0 ml to about 30.0 ml of glycoprotein solution.

26. (Original) A package according to Claim 24 in which said unit dose containers are provided to accommodate an uninterrupted dosage regimen basis of at least one month.